Current Status of Renal Xenotransplantation and Next Steps

Alfred J. Tector; Andrew B. Adams; Matt Tector

doi:10.34067/KID.0007152021

Current Status of Renal Xenotransplantation and Next Steps

Alfred J. Tector, Andrew B. Adams, Matt Tector

Surgery

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Renal transplantation is the preferred treatment of ESKD, but the shortage of suitable donor kidneys from the cadaver pool means that many patients with ESKD will not receive a kidney transplant. Xenotransplantation has long represented a solution to the kidney shortage, but the occurrence of antibody-mediated rejection has precluded its clinical development. Developments in somatic cell nuclear transfer in pigs and gene editing tools have led to the creation of new donor pigs with greatly improved crossmatches to patients. In addition, improvements in preclinical kidney xenotransplant survival using new anti-CD40/CD154-based immunosuppression have pushed xenotransplantation to the point where it is reasonable to consider initiating a clinical trial to evaluate this potential therapy in patients.

Original language	English (US)
Pages (from-to)	278-284
Number of pages	7
Journal	Kidney360
Volume	4
Issue number	2
DOIs	https://doi.org/10.34067/KID.0007152021
State	Published - Feb 1 2023

Bibliographical note

Publisher Copyright:
© 2022 by the American Society of Nephrology.

Keywords

basic science
transplantation
xenotransplantation

PubMed: MeSH publication types

Journal Article
Research Support, N.I.H., Extramural

Access

10.34067/KID.0007152021

OpenUrl availability

Full text

Cite this

@article{e5b94bcbe3444ecea181aa7f514a6f97,

title = "Current Status of Renal Xenotransplantation and Next Steps",

abstract = "Renal transplantation is the preferred treatment of ESKD, but the shortage of suitable donor kidneys from the cadaver pool means that many patients with ESKD will not receive a kidney transplant. Xenotransplantation has long represented a solution to the kidney shortage, but the occurrence of antibody-mediated rejection has precluded its clinical development. Developments in somatic cell nuclear transfer in pigs and gene editing tools have led to the creation of new donor pigs with greatly improved crossmatches to patients. In addition, improvements in preclinical kidney xenotransplant survival using new anti-CD40/CD154-based immunosuppression have pushed xenotransplantation to the point where it is reasonable to consider initiating a clinical trial to evaluate this potential therapy in patients.",

keywords = "basic science, transplantation, xenotransplantation",

author = "Tector, {Alfred J.} and Adams, {Andrew B.} and Matt Tector",

note = "Publisher Copyright: {\textcopyright} 2022 by the American Society of Nephrology.",

year = "2023",

month = feb,

day = "1",

doi = "10.34067/KID.0007152021",

language = "English (US)",

volume = "4",

pages = "278--284",

journal = "Kidney360",

issn = "2641-7650",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Current Status of Renal Xenotransplantation and Next Steps

AU - Tector, Alfred J.

AU - Adams, Andrew B.

AU - Tector, Matt

PY - 2023/2/1

Y1 - 2023/2/1

N2 - Renal transplantation is the preferred treatment of ESKD, but the shortage of suitable donor kidneys from the cadaver pool means that many patients with ESKD will not receive a kidney transplant. Xenotransplantation has long represented a solution to the kidney shortage, but the occurrence of antibody-mediated rejection has precluded its clinical development. Developments in somatic cell nuclear transfer in pigs and gene editing tools have led to the creation of new donor pigs with greatly improved crossmatches to patients. In addition, improvements in preclinical kidney xenotransplant survival using new anti-CD40/CD154-based immunosuppression have pushed xenotransplantation to the point where it is reasonable to consider initiating a clinical trial to evaluate this potential therapy in patients.

AB - Renal transplantation is the preferred treatment of ESKD, but the shortage of suitable donor kidneys from the cadaver pool means that many patients with ESKD will not receive a kidney transplant. Xenotransplantation has long represented a solution to the kidney shortage, but the occurrence of antibody-mediated rejection has precluded its clinical development. Developments in somatic cell nuclear transfer in pigs and gene editing tools have led to the creation of new donor pigs with greatly improved crossmatches to patients. In addition, improvements in preclinical kidney xenotransplant survival using new anti-CD40/CD154-based immunosuppression have pushed xenotransplantation to the point where it is reasonable to consider initiating a clinical trial to evaluate this potential therapy in patients.

KW - basic science

KW - transplantation

KW - xenotransplantation

UR - http://www.scopus.com/inward/record.url?scp=85162213225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85162213225&partnerID=8YFLogxK

U2 - 10.34067/KID.0007152021

DO - 10.34067/KID.0007152021

M3 - Review article

C2 - 36821619

AN - SCOPUS:85162213225

SN - 2641-7650

VL - 4

SP - 278

EP - 284

JO - Kidney360

JF - Kidney360

IS - 2

ER -

Current Status of Renal Xenotransplantation and Next Steps

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this